Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06091826
Other study ID # v1.2
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 21, 2023
Est. completion date September 30, 2023

Study information

Verified date October 2023
Source NFL Biosciences SAS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PRECESTO is a randomized, double-blind, cross-over trial on 34 smokers who do not want to stop smoking and get high satisfaction from smoking. The primary objective is to assess efficacy of NFL-101 in reducing the positive reinforcing properties of cigarettes compared to placebo measured by the modified Cigarette Evaluation Questionnaire (mCEQ) "Smoking Satisfaction" (items 1, 2, and 12) subscale.


Description:

PRECESTO is a monocentric, placebo-controlled, randomized and double-blind Phase 2a exploratory study, with a crossover covering two periods of 28 days each, including 34 smokers who do not want to quit and have high smoking satisfaction. Each participant is his or her own control and receives, on a random and alternating basis, either NFL-101 or the placebo at the start of each of the two periods. At the end of the study, all the participants received one dose of NFL-101 and one dose of the placebo. For each participant, the order in which NFL-101 and the placebo are administered is kept secret. For each period, the participants receive the treatments on day 1 (D1) then answer, with complete independence, the modified Cigarette Evaluation Questionnaire (mCEQ) on days 4 (D4), 7 (D7), 14 (D14), 21 (D21) and 28 (D28). The objective is to assess the safety and efficacy of NFL-101 as a pretreatment for smoking cessation, NFL-101 beeing administered a few days or weeks before a quit attempt while smokers are asked to smoke ad libitum (meaning to continue either to try to smoke the same amount or to smoke freely). It is indeed recognized that reducing satisfaction from smoking before a quit attempt begins to undermine the learned association between smoking and reward and thus promotes the success of these attempts.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date September 30, 2023
Est. primary completion date September 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Equipped with a web connection via a computer or tablet; - Subject currently smoking at least 10 cigarettes per day; - Exhaled CO = 9 ppm; - Subject with a mCEQ Satisfaction subscale score = 4 - Subject not wanting to stop smoking (MTSS score = 2) - Subject not under tobacco cessation therapy since at least 30 days; - Considered as healthy for the study after a comprehensive clinical assessment (detailed medical history and complete physical examination); - For women of childbearing potential: commitment to consistently and correctly use of a highly effective contraceptive measure: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner or sexual abstinence for the duration of the trial; - Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months); - Negative pregnancy test at screening visit; - Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests). Individual values out of the normal range can be accepted if judged clinically non relevant by the investigator; - Negative prick test at screening visit for the whole study product (extract of Tobacco leaf and NaCL), and positive for histamine; - Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research; - Subject having signed the informed consent agreement. Exclusion Criteria: - Pregnancy and breastfeeding; - Concomitant participation to another clinical trial; - Concomitant active infectious diseases; - Suicidal or depressive state - Positive results of screening for drugs of abuse - History or presence of drug or alcohol abuse (alcohol consumption > 40 grams / day); - Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study (for subjects in France only); - Subject who, in the judgment of the investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development.

Study Design


Intervention

Drug:
NFL-101
Subcutaneous injections
Placebo
Subcutaneous injections

Locations

Country Name City State
France Eurofins Optimed Gières Isère

Sponsors (1)

Lead Sponsor Collaborator
NFL Biosciences SAS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of smoking satisfaction Success in achieving a 1 point reduction in the mCEQ "Smoking Satisfaction" subscale at Day 4
Secondary Change of smoking satisfaction Success in achieving a 1 point reduction in mCEQ "Smoking Satisfaction" subscale at Day 7, at Day 14, at Day 21 and at Day 28
Secondary Change in psychological reward, aversion, enjoyment of respiratory tract sensation and craving Success in achieving a 1 point reduction in mCEQ "Psychological Reward"; "Aversion"; "Enjoyment of Respiratory Tract Sensations"; and "Craving Reduction" subcales at Day 4, at Day 7, at Day 14, at Day 21 and at Day 28
Secondary "Have you found your urges to smoke stronger or weaker than usual in the last 24 hours?" With response options of "much stronger," "slightly stronger," "same as before," "slightly weaker," and "much weaker" at Day 4, at Day 7, at Day 14, at Day 21 and at Day 28
Secondary "Have you found cigarettes more or less enjoyable than usual in the last 24 hours?" With response options of "much more enjoyable," "slightly more enjoyable," "same as before," "slightly less enjoyable," and "much less enjoyable" at Day 4, at Day 7, at Day 14, at Day 21 and at Day 28
Secondary Preference question : "Is there one of the two administrations that made you want to quit smoking or reduce your cigarette consumption more than the other?" With response options of administration 1, administration 2, I dont know, imponderable factors (for example covid, death of a relative, job loss, etc.) do not allow me to answer at EOS visit
See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT04617444 - The ESTxENDS Trial- Substudy on Effects of Using Electronic Nicotine Delivery Systems (ENDS) on Olfactory Function N/A
Completed NCT02796391 - Facilitating Smoking Cessation With Reduced Nicotine Cigarettes Phase 2
Completed NCT03397511 - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City N/A
Not yet recruiting NCT05188287 - A Culturally Tailored Smartphone Application for African American Smokers N/A
Recruiting NCT05264428 - The Effect of Honey on Lessening the Withdrawal Symptoms N/A
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT04133064 - Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study N/A
Completed NCT03187730 - Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants Phase 4
Completed NCT03474783 - To Explore the Factors Affecting the Effectiveness of Smoking Cessation N/A
Completed NCT04635358 - Feasibility Study of Smoking Cessation for the Staff of a Hospital Center N/A
Terminated NCT03670264 - BE Smokefree: Behavioral Economics Incentives to Engage Adolescents in Smoking Cessation N/A
Not yet recruiting NCT06307496 - VIDeOS for Smoking Cessation N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02997657 - Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial N/A
Completed NCT02905656 - Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit N/A
Completed NCT02562521 - A Smoking Cessation Intervention for Yale Dining Employees Phase 4
Completed NCT02239770 - Pharmacokinetics of Nicotine Film in Smokers N/A
Recruiting NCT02422914 - Benefits of Tobacco Free Cigarette N/A